SNDX-5613

Product Name: SNDX-5613
CAS No.: 2169919-21-3
Chemical Name: SNDX-5613
Synonyms: SNDX-5613;Revumenib;SNDX-5613 SNDX5613;SNDX-5613, 10 mM in DMSO;acute,Leukemia,inhibit,lymphoblastic,Epigenetic Reader Domain,Inhibitor,AML,Menin,ALL,SNDX 5613,SNDX-5613,SNDX5613,MLL,myeloid;N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide;Benzamide, N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)-
CBNumber: CB47244410
Molecular Formula: C32H47FN6O4S
Formula Weight: 630.82
MOL File: 2169919-21-3.mol

More

Less

SNDX-5613 Property

Boiling point:: 739.1±70.0 °C(Predicted)
Density: 1.28±0.1 g/cm3(Predicted)
solubility: DMSO:30.0(Max Conc. mg/mL);47.56(Max Conc. mM)
pka: 11.10±0.40(Predicted)
form: Solid
color: White to off-white
InChIKey: FRVSRBKUQZKTOW-YOCNBXQISA-N
SMILES: C(N(CC)C(C)C)(=O)C1=CC(F)=CC=C1OC1=CN=CN=C1N1CC2(CCN(C[C@@H]3CC[C@@H](NS(CC)(=O)=O)CC3)CC2)C1

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

N-Bromosuccinimide Price

ChemScene

Product number: CS-0120274
Product name: SNDX-5613
Purity: 99.62%
Packaging: 5mg
Price: $500
Updated: 2021/12/16

ChemScene

Product number: CS-0120274
Product name: SNDX-5613
Purity: 99.62%
Packaging: 10mg
Price: $850
Updated: 2021/12/16

ChemScene

Product number: CS-0120274
Product name: SNDX-5613
Purity: 99.62%
Packaging: 25mg
Price: $1250
Updated: 2021/12/16

ChemScene

Product number: CS-0120274
Product name: SNDX-5613
Purity: 99.62%
Packaging: 50mg
Price: $1850
Updated: 2021/12/16

ChemScene

Product number: CS-0120274
Product name: SNDX-5613
Purity: 99.62%
Packaging: 100mg
Price: $2750
Updated: 2021/12/16

More

Less

SNDX-5613 Chemical Properties,Usage,Production

Uses

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].

in vivo

Revumenib (SNDX-5613) shows in vivo plasma IC₅₀ of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts^[1].

References

[1] A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).

SNDX-5613 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

SNDX-5613 Suppliers

China 76 United States 4 Global 80

NANJING WEDO PHARMATECH CO.,LTD.

Tel: 15189836218
Email: wedo-chem@huawe.com
Country: China
ProdList: 306
Advantage: 58

Taizhou Zhongzhi Biotechnology Co., Ltd

Tel: 13012344321
Email: 3995296515@qq.com
Country: China
ProdList: 8219
Advantage: 58

Suzhou Meidi Senuo Pharmaceutical Technology Co., Ltd.

Tel: 13771642864
Fax: 1078336263
Email: snhuyu_2008@126.com
Country: China
ProdList: 1165
Advantage: 58

Shanghai Tachizaki Biomedical Research Center

Tel: 18014399201
Email: sales@chemlab-tachizaki.com
Country: China
ProdList: 2703
Advantage: 58

SINO High Goal Chemical Technology Co., Ltd.

Tel: 021-57646680 18306277365
Fax: 2469917557
Email: sunkai@chembiobanksh.com
Country: China
ProdList: 2040
Advantage: 55

ShangHai Caerulum Pharma Discovery Co., Ltd.

Tel: 18149758185
Email: sales-cpd@caerulumpharma.com
Country: China
ProdList: 3506
Advantage: 58

Sichuan Wei Keqi Biological Technology Co., Ltd.

Tel: 028-81700200 18116577057
Fax: 028-81705658
Email: 3003855609@qq.com
Country: China
ProdList: 7778
Advantage: 56

Shanghai Lollane Biological Technology Co.,Ltd.

Tel: 021-52996696，15000506266 15000506266
Fax: +86-21-52996696
Country: China
ProdList: 4763
Advantage: 55

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

More

Less

View Lastest Price from SNDX-5613 manufacturers

Wuhan Nutra Biotechnology Co.,Ltd

Product: SNDX-5613 2169919-21-3
Price: US $1.00/box
Min. Order: 1box
Purity: 98%
Supply Ability: 1
Release date: 2022-11-19

2169919-21-3, SNDX-5613Related Search:

SNS-062 PF-04929113 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide hydrochloride N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea

SNDX-5613

acute,Leukemia,inhibit,lymphoblastic,Epigenetic Reader Domain,Inhibitor,AML,Menin,ALL,SNDX 5613,SNDX-5613,SNDX5613,MLL,myeloid

Benzamide, N-ethyl-2-[[4-[7-[[trans-4-[(ethylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-5-fluoro-N-(1-methylethyl)-

SNDX-5613 SNDX5613

Revumenib

N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

SNDX-5613, 10 mM in DMSO

2169919-21-3